He is a biotech industry veteran with a dual experience in Silicon Valley and in France.
General Partner of Truffle Capital, a leading venture capital firm based in Paris. Founder of three biotechnology companies: SangStat, Conjuchem, and DrugAbuse of which two have gone public: SangSat in 1993 (Nasdaq: SANG) and Conjuchem in 2000 (Toronto Stock Exchange: CJB)
He is the Honorary Chairman of France Biotech, the French Industry Association and former Vice-Chairman of Europabio, the European Biotech Industry Association.
M. Pouletty is owner of 29 patents.
Board member of Carmat, Cytomics, Deinove, Immune Targeting Systems Ltd (England), Innate Pharma, Neovacs, Pharnext, Symetis (Switzerland),Theraclion, Vexim and Wittycell.
Philippe Pouletty was awarded the «Chevalier de la Légion d'Honneur».
MD from University of Paris VI, immunology, laureate from Pasteur Institute. Post-doctoral research fellow at Stanford University and 1999 laureate of the American Liver Foundation
Former Member of the “Conseil Stratégique pour l'Attractivité de la France”, chaired by the French prime minister
Biology graduate (Master 2). After 17 years of experience in the diagnostics industry sector, he took the operational helm of bmd in 2009.
Law graduate, holder of an MBA, specialised in SME personnel management in the last twenty years.
Molecular biology graduate. After fifteen years devoted to production at Biomérieux, he is in charge of the entire industrialisation, production and quality sector at BMD (21 people).
Co-founder of the company and a pharmacy graduate, he is responsible for the strategic part of distribution and product flow management (12 people). He is also in charge of the technical departments (5 people).
